Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | H. Pei, S. Parthasarathy, S. Joseph, W.McMillen, X. Xu, S. Castaneda, I. Inigo, K. Britt, B. Anderson, G. Zhao, S. Sawyer, D. Beight, T. Kaoudi, C. Iyer, H. Bian, A. Pappas, D. Surguladze, D. Schaer, K. Benhadji, M. Kalos, Kyla Driscoll | ||||||||||||
Title | LY3200882, a novel, highly selective TGFbetaRI small molecule inhibitor | ||||||||||||
|
|||||||||||||
URL | http://www.abstractsonline.com/pp8/#!/4292/presentation/7901 | ||||||||||||
Abstract Text |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LY3200882 | LY 3200882 | TGFBR1 inhibitor 16 | LY3200882 is a small molecule that inhibits TGFBR1, potentially resulting in increased anti-tumor immune response and decreased tumor growth (AACR Annual Meeting 2017, Abstract nr 955). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|